摘要
Abstract
Objective:To investigate the effect of thrombocytopenia in patients with malignant tumor who were treated with recombinant human interleukin-11 derivatives.Methods:40 patients with malignant tumor were selected from January 2012 to January 2014.With a self control,this study divided into 2 periods,in the first treatment cycles,did not given rhIL-11 after chemotherapy,while in the second cycles,patients were given rhIL-11 within 24~48 h after chemotherapy,then we compared thrombocytopenic conditions in two groups.Results:In those 40 patients the lowest value of platelet count in the second cycle was significantly higher than that in the first period(P<0.05);the duration of platelet count less than 50 × 109/L was significantly shorter than the first cycles(P<0.05),and the time of platelet recovery to normal value also was obviously shorter than the first cycles(P<0.05);the incidence of platelet transfusion was significantly less than the first cycles(P<0.05);none of the patients occurred hemorrhage in second cycles,and the adverse reaction was mild.Conclusion:RhIL-11 derivatives used in patients with malignant tumor has significantly effect on prevention of thrombocytopenia after chemotherapy,and the adverse reactions is mild, so it is worthy of popularization and application.关键词
恶性肿瘤/化疗/血小板减少/重组人白介素-11衍生物Key words
Malignant tumor/Chemotherapy/Thrombocytopenia/Recombinant human interleukin -11 derivatives
